drugset / Trial / NCT04445285

Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure

NCT04445285

Phase 2 Recruiting 44 enrolled Jon Simmons University of South Alabama · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce 28-day mortality.

Timeline

Start
2020-04-28
Primary completion
2021-11-30
Completion
2022-02-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject dornase alfa Protein / enzyme biologic 2.5 mg Inhaled

Indications